reviewTop 1% cited
Organic Carbamates in Drug Design and Medicinal Chemistry
Journal of Medicinal Chemistry · 2015 · Vol. 58(7) · pp. 2895–2940
Arun K. Ghosh✉(Purdue University West Lafayette)Margherita Brindisi(Purdue University West Lafayette)
Abstract
The carbamate group is a key structural motif in many approved drugs and prodrugs. There is an increasing use of carbamates in medicinal chemistry and many derivatives are specifically designed to make drug-target interactions through their carbamate moiety. In this Perspective, we present properties and stabilities of carbamates, reagents and chemical methodologies for the synthesis of carbamates, and recent applications of carbamates in drug design and medicinal chemistry.
Chemical Synthesis and AnalysisClick Chemistry and ApplicationsSynthesis and Biological EvaluationChemistryCarbamateMoietyCombinatorial chemistryDrugProdrugOrganic chemistryReagentPharmacologyBiochemistry
MeSH terms
Antiviral AgentsCarbamatesChemistry, PharmaceuticalDrug StabilityHepatitis CHumansProdrugsRNA-Dependent RNA PolymeraseDrug DesignSerine Proteinase InhibitorsCysteine Proteinase InhibitorsHIV ProteaseHIV Protease InhibitorsViral Nonstructural ProteinsAmyloid Precursor Protein Secretases
Funding
- Purdue University
- National Institute of General Medical Sciences
Citations
697
FWCI
19.58
field-weighted impact
References
359
Percentile
100%
vs. same field & year
Citations per year
Cited by
Global trends in pesticides: A looming threat and viable alternatives
Ecotoxicology and Environmental Safety · 2020 · 537 citations
References
Structural basis of substrate specificity in the serine proteases
Protein Science · 1995 · 828 citations
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
European Journal of Cancer · 1998 · 1,233 citations
Prodrugs: design and clinical applications
Nature Reviews Drug Discovery · 2008 · 1,565 citations
Protease Inhibitors: Current Status and Future Prospects
Journal of Medicinal Chemistry · 2000 · 878 citations
The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity
Journal of Pharmacology and Experimental Therapeutics · 2003 · 591 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.
